Medtronic Completes Acquisition of CathWorks

April 20, 2026—Medtronic announced it has completed its acquisition of CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease with its fractional flow reserve (FFR) diagnostic technology.

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Egg Medical Launches EggNest Complete Flex for Apron-Free Radiation Protection

April 9, 2026—Egg Medical announced the launch of EggNest Complete Flex radiation protection, which enables clinicians to safely work apron-free or with ultralight lead aprons.

Supira’s SUPPORT II Pivotal Trial of pVAD System Approved by FDA

April 9, 2026—Supira Medical, Inc. announced FDA approval to initiate the SUPPORT II pivotal trial of the Supira percutaneous ventricular assist device (pVAD) system.

ALL-RISE Compares CathWorks’ FFRangio to Invasive Pressure Wire Guidance

April 3, 2026—CathWorks announced 1-year clinical outcomes of the ALL-RISE trial.

ORBITA-CTO Shows PCI Improves Angina in Patients With Symptomatic Single-Vessel Coronary CTO

April 1, 2026—Results from the ORBITA-CTO trial demonstrated that percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) improved angina symptoms compared with a placebo procedure in patients with single-vessel disease.

PRO-TAVI: PCI Deferral Noninferior to PCI Before TAVR at 1 Year

April 1, 2026—Deferring percutaneous coronary intervention (PCI) until after transcatheter aortic valve replacement (TAVR) resulted in similar 1-year clinical outcomes compared with performing PCI before TAVR in older patients with severe aortic stenosis (AS) and coronary artery disease (CAD), according to results of the PRO-TAVI trial presented at ACC.26 and simultaneously published in The Lancet.

IVUS-CHIP and OPTIMAL Studies Probe Role of IVUS in Complex PCI and Left Main Disease

March 30, 2026—Routine intravascular ultrasound (IVUS) guidance during percutaneous coronary intervention (PCI) did not improve clinical outcomes compared with angiography guidance in two contemporary randomized trials presented at ACC.26 and published in The New England Journal of Medicine.

BCIS-3 Finds No Benefit, Signals Harm With LV Unloading in PCI

March 30, 2026—Use of a temporary mechanical pump to achieve left ventricular (LV) unloading during percutaneous coronary intervention (PCI) did not improve outcomes compared with PCI alone in patients with severe coronary artery disease and impaired LV function, according to results of the BCIS-3 trial presented at ACC.26 and published in The New England Journal of Medicine.

vFFR Demonstrates Comparable Outcome to Standard FFR in FAST-III Trial

March 29, 2026—A novel, minimally invasive method for assessing coronary lesion physiology using vessel fractional flow reserve (vFFR) demonstrated outcomes comparable to conventional fractional flow reserve (FFR) in the randomized FAST-III trial, presented at the American College of Cardiology’s Annual Scientific Session (ACC.26), according to a company press release.

Philips Launches IntraSight Plus Interventional Guidance Platform 

March 30, 2026—Royal Philips announced the launch of the IntraSight Plus interventional guidance platform, which has received FDA 510(k) clearance in the United States and CE Mark approval Europe.

Delayed Reperfusion With Left-Ventricular Support Evaluated in STEMI DTU

March 28, 2026—The STEMI DTU randomized trial of ST-elevation myocardial infarction and door-to-unloading time showed that delayed reperfusion with left-ventricular (LV) support to reduce heart damage resulted in no significant difference compared with standard immediate percutaneous coronary intervention (PCI) in patients with heart attacks at risk for a large amount of heart damage.

Relief Cardiovascular’s RELIEF-FIH Meets All 3-Month Endpoints

March 9, 2026—Relief Cardiovascular, Inc. announced 90-day results from the first-in-human (FIH), prospective, multicenter RELIEF-FIH study of the Relief system for the treatment of heart failure (HF) congestion.

CathWorks’ FFRangio Compared With Invasive Pressure Wire-Guided PCI in Medicare Outcomes Data Through 2 Years

March 9, 2026—CathWorks announced the presentation of outcomes data from a cohort of more than 4,000 Medicare patients demonstrating that angiography-derived physiology (ADP) using CathWorks FFRangio resulted in similar clinical outcomes compared with invasive pressure wire-guided percutaneous coronary intervention (PCI) through 2 years.

Abbott’s CardioMEMS Hero PA Pressure Reader Approved by FDA for Remote HF Monitoring

March 2, 2026—Abbott announced FDA approval of the CardioMEMS Hero device, its next-generation pulmonary artery (PA) pressure reader to support the care of patients with heart failure (HF).

Gentuity Collaborates With GE HealthCare to Market Intravascular Imaging Solutions in the United States

February 27, 2026—Gentuity LLC announced a commercial collaboration with GE HealthCare to increase the availability of Gentuity’s high-frequency optical coherence tomography (HF-OCT) imaging system and Vis-Rx Prime micro-imaging catheter.

Salus Scientific AeroShield Radiation Protection Used in First Clinical Case

February 10, 2026—Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the first clinical use of AeroShield, a table-mounted, inflatable enhanced radiation protection device (ERPD), marking what the organizations described as the first deployment of the technology in a live catheterization laboratory setting.

SCAI Expert Opinion Explores Angiography-Derived Physiology for Coronary Assessment

February 5, 2026—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the publication of an expert opinion document that examines the evolving role of angiography-derived physiology (ADP) for the assessment and management of coronary artery disease.

Medtronic to Acquire CathWorks

February 5, 2026—Medtronic announced it will exercise its option to acquire CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease (CAD) with its fractional flow reserve (FFR) diagnostic technology.

ALPHA-PE Research Fund Launched to Advance Pulmonary Embolism Care

February 5, 2026—AngioDynamics, Inc. and The PERT Consortium announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism (PE) research.